Detailed Narrative
Q1 FY26 Performance Overview
Marksans Pharma reported a 5% year-on-year increase in operating revenue to INR620 crores for Q1 FY26, despite a seasonally soft quarter. Gross profit grew 8.9% YoY to INR358.2 crores, with gross margin expanding by 209 basis points to 57.8%. However, EBITDA declined to INR100.1 crores, resulting in a 16.1% EBITDA margin, a 560 basis point decrease from the previous year. Profit after tax also saw a significant decline of 34.7% YoY, settling at INR58.2 crores, with EPS at INR1.3.
Geographical Performance and Market Dynamics
The US and North America market demonstrated strong growth, with revenue increasing 30.6% YoY to INR327.6 crores, driven by new product launches in digestive and pain management segments. Conversely, the UK and EU Formulation segment recorded INR203.8 crores, experiencing a seasonally soft quarter and high single-digit price erosion. The Australia and New Zealand market contributed INR57 crores, while the rest of the world generated INR31.6 crores. Management noted early signs of demand recovery in Q2, expecting momentum to strengthen through the year.
Margin Dynamics and Cost Management
Gross margin expanded to 57.8% due to the liquidation of high-cost inventories and benefits from softening input costs. However, EBITDA margin was impacted by several non-recurring📎 factors, including integration-related expenses, a one-time📎 provision of INR10.48 crores for the emerging market division, and a mark-to-market forex loss of INR6.2 crores. Employee expenses also increased due to recruitment for the new Goa facility, though management expects these costs not to rise further.
Strategic Initiatives and Pipeline
The company continues to strengthen its product pipeline, having received 3 regulatory approvals from the U.S. FDA and U.K. MHRA during the quarter. Four high-margin liquid products were successfully launched in the U.K., aligning with the strategy to build a diversified and margin-accretive portfolio. The US order book currently stands at $220 million, with execution for $45-50 million expected to commence in Q3 FY26.
Regulatory and Operational Updates
Marksans Pharma received an Establishment Inspection Report (EIR) from the U.S. FDA for the inspection conducted at its subsidiary, Time-Cap Laboratories. The newly constructed facility in Goa is structurally nearing completion, with a focus on enhancing operational efficiencies and scaling capacity for multi-dosage manufacturing forms. The Teva facility's utilization is improving, now trending close to INR500 crores in Q1, up from INR400 crores in Q4 FY25, with an aim to reach INR800 crores.
Working Capital and Liquidity
The working capital cycle for the quarter stood at 159 days, primarily impacted by accelerated shipments to the U.S. ahead of anticipated tariff implications. Despite this, the company remains debt-free, maintaining a healthy cash balance of INR711 crores as of June 30, 2025. Management affirmed its strong balance sheet and readiness to make additional investments in the U.S. if needed, without shying away.
Outlook and Challenges
The company anticipates FY26 revenue to be "very close to INR3,000 crores or maybe shy away from INR3,000 crores." EBITDA margins are expected to improve quarter-on-quarter but remain "flattish" year-on-year. The UK market is projected to be "flattish" for the year, while Australia and New Zealand are expected to show "nominal growth" year-on-year. Global tariff uncertainties continue to pose a risk, creating a cascading impact on demand and pricing across markets, which the company is navigating through disciplined execution and strategic agility.